JP2019537608A - 癌の処置のための医薬組成物および方法 - Google Patents

癌の処置のための医薬組成物および方法 Download PDF

Info

Publication number
JP2019537608A
JP2019537608A JP2019524973A JP2019524973A JP2019537608A JP 2019537608 A JP2019537608 A JP 2019537608A JP 2019524973 A JP2019524973 A JP 2019524973A JP 2019524973 A JP2019524973 A JP 2019524973A JP 2019537608 A JP2019537608 A JP 2019537608A
Authority
JP
Japan
Prior art keywords
methyl
amino
tyrosine
propanoate
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019524973A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019537608A5 (enExample
Inventor
ホフマン，スティーブン
Original Assignee
タイム，インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/351,966 external-priority patent/US10272068B2/en
Application filed by タイム，インコーポレーテッド filed Critical タイム，インコーポレーテッド
Publication of JP2019537608A publication Critical patent/JP2019537608A/ja
Publication of JP2019537608A5 publication Critical patent/JP2019537608A5/ja
Priority to JP2022184577A priority Critical patent/JP2023018029A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A61K38/34—Melanocyte stimulating hormone [MSH], e.g. alpha- or beta-melanotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Emergency Medicine (AREA)
JP2019524973A 2016-11-15 2017-11-15 癌の処置のための医薬組成物および方法 Pending JP2019537608A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022184577A JP2023018029A (ja) 2016-11-15 2022-11-18 癌の処置のための医薬組成物および方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15/351,966 US10272068B2 (en) 2012-01-17 2016-11-15 Pharmaceutical compositions and methods
US15/351,966 2016-11-15
PCT/US2017/061682 WO2018093820A1 (en) 2016-11-15 2017-11-15 Pharmaceutical compositions and methods for the treatment of cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022184577A Division JP2023018029A (ja) 2016-11-15 2022-11-18 癌の処置のための医薬組成物および方法

Publications (2)

Publication Number Publication Date
JP2019537608A true JP2019537608A (ja) 2019-12-26
JP2019537608A5 JP2019537608A5 (enExample) 2020-12-24

Family

ID=60570232

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019524973A Pending JP2019537608A (ja) 2016-11-15 2017-11-15 癌の処置のための医薬組成物および方法
JP2022184577A Withdrawn JP2023018029A (ja) 2016-11-15 2022-11-18 癌の処置のための医薬組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022184577A Withdrawn JP2023018029A (ja) 2016-11-15 2022-11-18 癌の処置のための医薬組成物および方法

Country Status (12)

Country Link
EP (1) EP3541411A1 (enExample)
JP (2) JP2019537608A (enExample)
KR (2) KR20190084291A (enExample)
CN (1) CN110167580A (enExample)
AU (1) AU2017361080A1 (enExample)
BR (1) BR112019009799A2 (enExample)
CA (1) CA3040922A1 (enExample)
EA (1) EA201991192A1 (enExample)
IL (1) IL266486A (enExample)
MX (1) MX2019005450A (enExample)
PH (1) PH12019500758A1 (enExample)
WO (1) WO2018093820A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020276605A1 (en) 2019-05-14 2022-01-20 Tyme, Inc. Compositions and methods for treating cancer
CA3157855A1 (en) * 2019-10-15 2021-04-22 Tyme, Inc. Alkylesters of alpha-methyl-dl-tyrosine for use in treating cancer
AU2021207666A1 (en) * 2020-01-17 2022-09-01 Tyme, Inc. Tyrosine derivatives for modulating cancer
CN111358777A (zh) * 2020-02-24 2020-07-03 军事科学院军事医学研究院环境医学与作业医学研究所 一种提高外周血单个核细胞线粒体功能的方法和应用
US10905698B1 (en) 2020-05-14 2021-02-02 Tyme, Inc. Methods of treating SARS-COV-2 infections
WO2022120039A2 (en) * 2020-12-02 2022-06-09 Steven Hoffman Compositions and methods for modulating cancer in non-human mammals

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015509101A (ja) * 2012-01-17 2015-03-26 タイム，インコーポレーテッド 薬学的組成物及び方法
US20160263149A1 (en) * 2012-01-17 2016-09-15 Tyme, Inc. Pharmaceutical compositions and methods
JP2016534071A (ja) * 2013-10-22 2016-11-04 タイム，インコーポレーテッド チロシン誘導体及びそれを含む組成物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225435A (en) 1990-05-18 1993-07-06 Yale University Soluble melanin
US20060078494A1 (en) * 2004-09-24 2006-04-13 Sapphire Therapeutics, Inc. Use of inhibitors of 24-hydroxylase in the treatment of cancer
WO2006032299A1 (en) * 2004-09-24 2006-03-30 Susanna Miettinen Use of inhibitors of 24-hydroxylase in the treatment of cancer
US8481498B1 (en) * 2012-01-17 2013-07-09 Steven Hoffman Pharmaceutical compositions and methods

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015509101A (ja) * 2012-01-17 2015-03-26 タイム，インコーポレーテッド 薬学的組成物及び方法
US20160263149A1 (en) * 2012-01-17 2016-09-15 Tyme, Inc. Pharmaceutical compositions and methods
JP2016534071A (ja) * 2013-10-22 2016-11-04 タイム，インコーポレーテッド チロシン誘導体及びそれを含む組成物

Also Published As

Publication number Publication date
CN110167580A (zh) 2019-08-23
EA201991192A1 (ru) 2019-10-31
JP2023018029A (ja) 2023-02-07
IL266486A (en) 2019-07-31
CA3040922A1 (en) 2018-05-24
MX2019005450A (es) 2019-07-04
BR112019009799A2 (pt) 2019-08-06
WO2018093820A1 (en) 2018-05-24
KR20190084291A (ko) 2019-07-16
EP3541411A1 (en) 2019-09-25
PH12019500758A1 (en) 2019-07-24
KR20230003314A (ko) 2023-01-05
AU2017361080A1 (en) 2019-05-02

Similar Documents

Publication Publication Date Title
JP7095028B2 (ja) 薬学的組成物及び方法
US10307465B2 (en) Pharmaceutical compositions and methods
US11052068B2 (en) Pharmaceutical compositions and methods
JP2023018029A (ja) 癌の処置のための医薬組成物および方法
US11103559B2 (en) Pharmaceutical compositions and methods
US20210386832A1 (en) Pharmaceutical Compositions And Methods

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201109

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201109

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210927

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220225

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220721